Healthcare Professionals

Arctic Front Advance

Cardiac CryoAblation Catheter

  • arctic-front-advance

Arctic Front Advance Cardiac CryoAblation Catheter

Arctic Front Advance™ Cardiac CryoAblation Catheter is the second generation of the world’s first cryoballoon indicated for the treatment of paroxysmal atrial fibrillation (PAF). Building upon the proven safety and efficacy of the original Arctic Front Cryoballoon, this technology provides an efficient approach to pulmonary vein isolation (PVI). The original Arctic Front product has a low complication risk and a proven efficacy in treating atrial fibrillation (AF). Over 180,000 patients in more than 1,300 centers worldwide have been treated with the cryoballoon.

Expand All

Overview

Overview

AF Advance

New EvenCool Cryo Technology

Arctic Front Advance features the new EvenCool™ Cryo Technology, which optimizes the delivery of coolant inside the balloon. By allowing more flexibility in balloon positioning to ablate the PVs, this new product enhancement is designed to improve physicians’ ability to treat patients with a wide variety of vein anatomies with less effort. 

Building on a Proven Platform: Arctic Front

An Efficient Approach to PVI

The Arctic Front cryoballoon provides a straightforward and efficient approach for isolating the pulmonary veins in the treatment of paroxysmal atrial fibrillation.

  • Arctic Front creates circumferential lesions1, using 2-3 applications per vein to achieve PVI2
  • Arctic Front does not require 3D mapping, reducing procedural complexity
  • Short, predictable procedure times allow you to treat more patients3

A Proven Approach to PVI

The North American Sustained Treatment of Paroxysmal Atrial Fibrillation (STOP AF) trial, a 26-center randomized, controlled study, confirmed the safety and efficacy of Arctic Front. 69.9% of patients achieved treatment success at 12 months.

Benefits of Cryoablation

The Arctic Front system uses cryo energy which offers a number of unique safety features:

  • Cryoadhesion improves contact and stability, minimizing the amount of fluoro used
  • Preserves the extracellular matrix and endothelial integrity1
  • Decreases risk of thrombus formation1
  • Demonstrates well demarcated lesions1

A Safe Approach to PVI

  • Clinical studies report no incidence of atrial-esophageal fistulas or perforation2,4
  • Low reported occurrence of left atrial tachycardia post procedure4
  • Cryoablation procedure event rate in the STOP AF pivotal study was a low 3.1%2

 

 

References

1

Sarabanda AV, Bunch TJ, Johnson SB, et al. Efficacy and safety of circumferential pulmonary vein isolation using a novel cryothermal balloon ablation system. J Am Coll Cardiol. November 15, 2005;46(10):1902-1912.

2

Medtronic Inc., Arctic Front Cardiac CryoAblation Catheter clinical reports, in support of FDA premarket approval.

3

Kojodjojo P, O’Neill MD, Lim PB, et al. Pulmonary venous isolation by antral ablation with a large cryoballoon for treatment of paroxysmal and persistent atrial fibrillation: medium-term outcomes and non-randomised comparison with pulmonary venous isolation by radiofrequency ablation. Heart. September 2010;96(17):1379-1384.

4

Van Belle Y, Janse P, Theuns D, Szili-Torok T, Jordaens L. One year follow-up after cryoballoon isolation of the pulmonary veins in patients with paroxysmal atrial fibrillation. Europace. November 2008:10(11):1271-1276.

How it Works

Specifications

IMPORTANT INFORMATION ON INDICATIONS, SAFETY AND WARNINGS

For listing of Indications, Contraindications, Warnings, Precautions, and Potential Adverse Events, please refer to the Instructions For Use .